Table 4

- Cox proportional hazards model regression of heart failure in patients with paroxysmal atrial fibrillation.

CharacteristicsUnivariate analysisMultiple analysis
hazard ratio (95% CI)P-valuehazard ratio (95% CI)P-value
CHA2DS2-VASc score1.214 (0.824-1.517)0.0861.204 (0.815-1.778)0.352
Low FMD2.651 (1.411-4.980)0.0023.207 (1.320-7.7975)0.010
LAD1.065 (1.037-1.093)0.0001.057 (1.022-1.093)0.001
LVD1.040 (1.009-1.072)0.0120.965 (0.915-1.019)0.201
LVEF0.978 (0.958-0.998)0.0280.992 (0.956-1.029)0.654
Smoking1.148 (0.650-2.703)0.321------
CHD1.166 (0.570-2.386)0.657------
TC0.814 (0.584-1.133)0.212------
TG0.822 (0.563-1.198)0.307------
LDL-C1.024 (0.698-1.880)0.0491.038 (0.638-1.688)0.882
Creatinine1.006 (1.0015-1.010)0.0091.002 (0.995-1.010)0.588
Homocysteine1.071 (1.042-1.102)0.0001.048 (1.012-1.086)0.008
Wafarin user0.893 (0.659-0.964)0.0450.897 (0.656-0.933)0.121
NOAC user0.935 (0.571-1.038)0.139------
Diuretics user1.131 (0.770-1.245)0.624------
Beita blocker user0.952 (0.671-1.358)0.475------
ACEI/ARB user0.836 (0.456-0.932)0.103------

CI: confidence interval, CHA2DS2-VASc: congestive heart failure, hypertension, age ≥75 (doubled), diabetes, stroke (doubled), vascular disease, age 65-74, and gender category (female), FMD: flow-mediated dilatation, LAD: left atrial diameter, LVD: left ventricular diameter, LVEF: left ventricular ejection fraction, CHD: coronary artery disease, TC: totol cholesterol, TG: triglyceride, LDL-C: low density lipoprotein-cholesterol, NOAC: non-vitamin K antagonist oral anticoagulant, ACEI: angiotension converting enzyme inhibitors, ARB: angiotensin receptor blocker